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ABSTRACT
Objective: Characterization of magnetic (MRI) features in women undergoing uterine
fibroid embolization (UFE) and identification of clinical correlates in an African
population. Materials and Methods: Patients with symptomatic fibroids who are
selected to undergo UFE at the hospital formed the study population. The baseline
MRI features, baseline symptom score, short‑term imaging outcome, and mid‑term
symptom scores were analyzed for interval changes. Assessment of potential
associations between short‑term imaging features and mid‑term symptom scores was
also done. Results: UFE resulted in statistically significant reduction (P < 0.001) of
dominant fibroid, uterine volumes, and reduction of symptom severity scores, which
were 43.7%, 40.1%, and 37.8%, respectively. Also, 59% of respondents had more
than 10 fibroids. The predominant location of the dominant fibroid was intramural.
No statistically significant association was found between clinical and radiological
outcome. Conclusion: The response of uterine fibroids to embolization in the African
population is not different from the findings reported in other studies from the west.
The presence of multiple and large fibroids in this study is consistent with the case
mix described in other studies of African-American populations. Patient counseling
should emphasize the independence of volume reduction and symptom improvement.
Though volume changes are of relevance for the radiologist in understanding the
evolution of the condition and identifying potential technical treatment failures, it
should not be the main basis of evaluation of treatment success.
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INTRODUCTION
Uterine fibroids, the most common benign tumor of the
female pelvis, affect 20–50% of women.[1] Hysterectomy
has been the traditional primary treatment for debilitating
fibroids. It is estimated that approximately one in three
women in the United States has undergone hysterectomy
by the age of 60 years. [2] Uterine fibroids account for
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approximately 67% of all hysterectomies performed in
middle‑aged women.[3] The associated health care costs
and morbidity are not trivial.
Since it was first described in 1995 for the treatment of
fibroids of the uterus, uterine fibroid embolization (UFE) has
been shown in numerous studies to be a highly successful
technique that alleviates fibroid‑related symptoms such
as heavy menstrual bleeding and bulk‑related symptoms.
Uterine fibroid embolization is performed by selectively
catheterizing the uterine arteries and embolizing the
perifibroid plexi with embolic articles. This results in
ischemic infarction of the fibroids. It is a valuable treatment
alternative to hysterectomy or myomectomy for many
women suffering with fibroids.
Uterine fibroids are not only associated with physical
symptoms, but also affect the quality of life (QOL) in
the affected women. It was, however, not possible until
recently to record specific details about the patient’s
QOL in a uniform and comparable manner due to lack of
standardized assessment tools. The uterine fibroid symptom
and QOL questionnaire (UFS‑QOL) presented by Spies and
colleagues in February 2002 is a practical and validated tool
for the objective assessment of disease‑specific symptoms,
their severity, and the impact of fibroids on different aspects
of the patient’s QOL.[4] The UFS‑QOL allows the comparison
of a patient’s condition before and after treatment by UFE
or alternative treatment options.
Though UFE has been used for a long time to treat
symptomatic uterine fibroids in the developed world,
it is a relatively new treatment option for fibroids in the
developing world. No local data, therefore, exist on both
the clinical and imaging outcome of this treatment option.
This study was undertaken to characterize the MRI imaging
features in women undergoing UFE and identify any clinical
correlates.
Clinical convention holds that symptoms and need for
treatment are, in large part, related to a combination of
the type of fibroid, position within the uterus, and fibroid
size. Fibroids are thus often grouped as one of the following
four types:
• Submucosal (beneath the mucosa, or uterine lining) are
immediately adjacent to or jut into the uterine cavity
• Intramural are entirely within the wall of the uterus
• Subserosal (beneath the serosa) distort the contour of
the outer surface of the uterus; and
• Pendunculated are attached to the uterus by a stalk
• Transmural fibroids are large fibroids which distort the
endometrium, occupy a component of the uterine wall,
distorting the external contour.[5]
2

The exact etiology of uterine fibroids is not clearly
understood, but the current working hypothesis is that
genetic predisposition, prenatal hormone exposure, and
the effects of hormones, growth factors, and xenoestrogens
cause fibroid growth. Known risk factors are African
descent, nulliparity, obesity, polycystic ovary syndrome,
diabetes, and hypertension.
Several studies have documented an increased incidence
of uterine fibroids in African women.[6,7] Some evidence
also indicates that African women are more likely than
Caucasian women to have larger and more symptomatic
fibroids at the time of treatment. [8-13] After accounting
for body mass index (BMI) and other known risk factors,
African women experience a higher incidence and relative
risk of uterine fibroids than other racial and ethnic groups
including Caucasian, Hispanic, and Asian women.
A few studies have been conducted on this subject in Africa.
The exact prevalence or incidence of uterine fibroids in the
continent is not known. A United States Census Bureau and
Population estimates report extrapolated the prevalence of
uterine fibroids at 1,649,105 cases (approximately 10‑20% of
the women population) in Kenya.[14] In a retrospective review
of 129 surgically managed cases of uterine leiomyoma
carried out at two large tertiary hospitals in the southwest
region of Nigeria over a period of 25 years, the commonest
anatomical positions of the fibroids were multiple positions
and intramural in 707 (60.9%) and 172 (14.8%) cases,
respectively. The higher prevalence rate of fibroids in
African women may be attributable to the gene encoding
fibroid development or a positive family history of fibroids,
myometrial irritation following a pelvic infection resulting in
abnormal uterine growth, or higher levels of estrogen.[13,14]
Imaging plays a critical role in diagnosis and management
of uterine fibroids. Ultrasonography is usually the initial
investigation for examining the female pelvis. Ideally, both
transabdominal (TA) and transvaginal (TV) scans should be
performed. TV scans are more sensitive for the diagnosis
of small fibroids; however, when the uterus is bulky or
retroverted, the uterine fundus may lie outside of the field
of view. TA views are often of limited value if the patient
is obese. Ultrasonography is highly operator dependent,
but in skilled hands, fibroids as small as 5 mm can be
demonstrated on transvaginal ultrasound.
CT scan is not the investigation of choice for the
characterization of pelvic masses. Uterine fibroids are often
seen incidentally on CT scans performed for other reasons.
MRI is the preferred method for accurately characterizing
pelvic masses. It has been shown to be more sensitive in
identifying uterine fibroids than ultrasound.[15‑17] It does
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not involve the use of ionizing radiation and it can readily
demonstrate the uterine zonal anatomy. Submucosal,
intramural, and subserosal fibroids are usually easily
differentiated with MRI and fibroids as small as 5 mm
in diameter can be demonstrated. Fibroids in relatively
unusual locations, such as within the cervix, can also be
identified. MRI is also used to both predict and assess
the response of fibroids to UFE. On T2‑weighted (T2W)
images, the normal endometrium shows high signal
intensity. Surrounding the endometrium is a low‑signal
band known as the junctional zone, which represents the
inner myometrium. The remainder of the myometrium is
of intermediate signal on T2W images.[18] MRI sequences
should include axial and sagittal T2W images as well as
T1‑weighted (T1W) images in at least one plane. The routine
use of gadolinium has been shown not to contribute to
either fibroid detection or characterization.[19] However,
gadolinium can be used to determine vascularity when
assessing the suitability of a fibroid for UFE.

literature review reveals that the peak imaging outcome
is at 3–6 months while the peak clinical outcome is at
6–24 months. This study, therefore, correlated the peak
imaging outcome at 3 months post treatment and the peak
clinical outcome 12 months after treatment.

Typically, non‑degenerate fibroids are well‑defined masses of
low signal intensity as compared to the myometrium on T2W
images and isointense to the myometrium on T1W images.

Methodology

In a study conducted in the United States, total
costs, including hospital care, procedure room, and
professional fees were estimated for 23 UFE procedures
and 17 myomectomy procedures. Myomectomy costs
averaged $7486 per procedure versus $6861 for UFE,
suggesting a trend toward lower costs for UFE.[20] A total of
120 UFEs have so far been done at the Aga Khan University
Hospital, Nairobi by a visiting specialist with over 15 years
of experience in UFE. The total cost of each procedure is
approximately 300,000 Kenya shillings (US$ 3530). This is
considered an extremely expensive procedure by most
Kenyans. The development of the Nairobi UFE service has
been described by Dr. Nigel Hacking and colleaques.[21]
The race of the catchment population of the study site is mainly
African, and therefore, uterine fibroids were presumed to be a
major health problem. Hysterectomy and myomectomy still
form the bulk of the treatment options for this disease. UFE
is a new treatment option in the management of fibroids in
the local setting. No data, therefore, exists on the radiological
and clinical response. This study was expected to be useful
in assessing the response of fibroids to UFE in the local
population. The data acquired was aimed to help doctors
to give adequate evidence‑based advice to their patients
regarding UFE for symptomatic fibroids. This would allow
the patients to make an informed choice.
Previous studies have correlated imaging and clinical
response at the same time period post UFE. However,
3

Specific objectives of this study
• Determine the enhancement pattern of the dominant
fibroid pre‑ and post‑embolization
• Calculate the baseline volume and the volume change
of the dominant fibroid and uterus pre‑ and 3–6 months
post‑embolization
• Enumerate the number of fibroids per patient
• Determine the location of the dominant fibroid
• Identify potential associations between the uterine
volume (UV), the volume of the dominant fibroid, and
the symptoms score.

MATERIALS AND METHODS
Study site
The study was carried out in the departments of radiology,
and obstetrics and gynecology at Aga Khan University
Hospital, Nairobi, an urban tertiary institution. This is a
264‑bed hospital based in Kenya but receiving patients
from all over east and central Africa. It has many specialized
clinics. The Department of Radiology has a 1.5 T General
Electric (GE) MRI scanner which is operational for 24 h a
day and 7 days a week.
Data collection
This was both a prospective and retrospective cohort study.
The data of the baseline MRI scans, baseline symptom scores,
and the 3‑month follow‑up MRI scans were captured and
stored in a registry at the radiology and the obstetrics and
gynecology departments. This represented the retrospective
aspect of the study. Symptom scores were then acquired
1 year after UFE during follow‑up at the gynecology clinic
and this formed the prospective aspect of the study.
Sample population
The sample population consisted of women with
symptomatic fibroids who chose to undergo UFE and
met the inclusion criteria which allowed them to have the
procedure done.
Study population
From the sample population, the study population was
selected as those with baseline MRI scans, baseline
symptom score, 3‑month follow‑up MRI scans, and
12‑month symptoms score.
Journal of Clinical Imaging Science | Vol. 5 | Issue 1 | Jan-Mar 2015
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Inclusion criteria

Statistical analysis

• All women undergoing UFE at Aga Khan University
Hospital, Nairobi who underwent contrast‑enhanced
pelvic MRI scans (UFE protocol) and filled the baseline
and follow‑up symptom scores
• Patients who signed an informed consent

The percentage volume reduction of the uterus and
dominant fibroid was calculated and presented as a mean,
standard deviation, and range value. The results of the
symptom score before and after UFE were also calculated
with the absolute percentage changes given as a mean.

Exclusion criteria

Spearman’s rank correlation coefficient was estimated to
identify potential associations between changes in the
symptom severity score, and the percentage UV and DFV
reduction. Statistical significance was considered to be
P < 0.05.

• Incomplete MRI studies and symptom score sheets
• Images of poor diagnostic quality

Statistical methods
Sample size calculation
A similar study by Reena et al., reported a mean decrease
in UV from 588.6 to 393.1 cm3, 3 months after UFE, which
resulted in a 33.5% change with a standard deviation of
16.1%.[22] The following formula was, therefore, used to
determine the required sample size:
n=

•
•
•
•

4σ 2 (Zσ + Z β )2

D2
where n is the required sample size
σ is the standard deviation of the mean
D is the expected size of the confidence interval
considered here as ± 4, and
Zα and Z β are the standard normal deviate values
corresponding to 95% and 90% power, respectively.

Substituting this information in the sample size formula,
the required sample size is a minimum of 65 patients with
complete radiological and clinical data.

Data management and analysis
Study data were retrieved from files and records and
then entered into a spreadsheet (Excel; Microsoft
Corporation Redmond, Washington USA). Analysis
was done using the Statistical Program for Social
Sciences (SPSS) version 17.
Dependent (response) variables
The primary outcome measures were the percentage
volume reduction of the uterus, dominant fibroid and the
symptom score changes.
Independent (predictor) variables
The independent variables for the primary analysis were
the baseline symptom and QOL score, the baseline uterine
and dominant fibroid volume (DFV).
The independent variables for the secondary analysis were
uterine and dominant fibroid changes and the symptom
and QOL scores.
4

Clinical assessment
A self‑administered symptom score filled out by all
study patients before UFE and at mid‑term follow‑up
visit, comprised eight questions pertaining to the type
and severity of symptoms. The eight symptom items
(questions 1–8) were summarized in a symptom severity
scale. Response options were presented as five‑level Likert
scales ranging from “not at all” (1) to “a very great deal”
(5) in response to “how distressed were you by...?” These
self‑administered questionnaires for mid‑term symptom
score were completed by patients during the follow‑up
visit at the gynecology clinic under the guidance of the
attending gynecologist or resident. In the unlikely scenario
that the patient failed to turn up for follow‑up at 1 year, an
email was sent out to her with an attached questionnaire.
The email addresses of all the participants were available
in the registry.

Radiological assessment
Imaging protocol
All the MRI scans were performed using a 1.5 T GM MRI
scanner. The following protocol was applied:
• Three plane localizer
• Axial T1 abdomen and pelvis
• Axial T1 fat‑saturated pelvis
• Axial T2 pelvis
• Coronal T2 pelvis
• Axial T1 fat‑saturated with contrast pelvis
• Sagittal T1 fat-saturated with contrast pelvis
The MRI images were independently reviewed by two
consultant radiologists with 5 years of experience post
residency in the picture archive and communication
system (PACS) workstation. Any discrepancy was resolved
by consensus. The baseline and follow‑up volume of the
uterus and of the dominant fibroid (largest fibroid before
therapy), the number of fibroids per patient (classified as
<5, 6–10, and >10), location of the dominant fibroid, and
enhancement of the dominant fibroid were determined.
Journal of Clinical Imaging Science | Vol. 5 | Issue 1 | Jan-Mar 2015
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• Based on the location of the center of the fibroid,
dominant fibroids were defined as being subserosal,
intramural, transmural, or submucosal using a
modification of the classification of Goodwin et al.[23]
• Volumes were determined by measuring the maximum
extent of the uterus and dominant leiomyoma in three
planes and multiplying the product by 0.5233 (ellipsoid
volume formula) as proposed by Orsini et al.[24]
Enhancement pattern of the fibroids was evaluated and
categorized as strongly enhancing, heterogeneously/
mildly enhancing, or non‑enhancing. The images were
anonymized for confidentiality using anonymizing software
in the PACS system (Agfa Impa × 6.4.5.4551).

Ethical considerations
This was a radiological study conducted utilizing the
images obtained during diagnostic work‑up and follow‑up.
Images were evaluated and measurements obtained for
analysis. The study did not influence direct patient care;
therefore, it was considered that individual consent was
not appropriate.
The primary investigator sought permission from the
hospital’s Chief of Staff to access patient files, if needed,
at the health records department. Any significant finding
that emerged during image evaluation which had not been
identified in the original report was communicated to the
referring physician by way of an addendum to the original
report. A high level of confidentiality was maintained. The
reviewers of the imaging data were blind to the patients’
biodata and clinical findings. The images were also
anonymized for extra confidentiality. The study investigator
had no conflict of interest to declare.

RESULTS
Mean age of the respondents was 41.7 years, with the
youngest and eldest respondents aged 27 and 49 years,
respectively [Table 1]. Baseline mean symptoms score, UV,
and dominant fibroid volume were 24.4, 847.1 cm3, and
209.2 cm3, respectively [Table 2]. Note that the symptom
severity score, based on a Likert scale, had a possible
minimum and maximum of 8 and 40, respectively. The
percentage reduction in the symptom score, UV, and DFV
after UFE was 37.8%, 40.1%, and 43.7%, respectively [Table 3].
The number of fibroids per participant was categorized into
three groups: 1–5, 6–10, and > 10. The number of participants
in each category was then presented as a percentage;
59% of the participants had more than 10 fibroids each,
while 21% and 20% of the participants had 1–5 and 6–10
fibroids each, respectively [Pie Chart 1]. Analysis of the
enhancement pattern of the dominant fibroids before and
5

after UFE revealed that all the dominant fibroids mildly
or moderately enhanced before UFE and none enhanced
after UFE [Table 4]. Evaluation of the position of dominant
fibroids revealed 78% being intramural/transmural, 12%
being submucosal, and 10% being subserosal [Pie Chart 2].
The percentage volume reduction of the dominant fibroid
and uterus was statistically significant (P < 0.001) [Table 5].
However, no statistically significant correlation was found
between the percentage volume change of both the
dominant fibroid and uterus and the symptom severity
score [Table 5].
Table 1: Mean and distribution of the age of the participants
Mean

Std. Dev.

Min.

Max.

41.7

5.2

27

49

Age (years)

Table 2: Baseline symptom scores, baseline volume of the
dominant fibroid, and baseline volume of uterus of the
participants
Baseline symptom score
Baseline uterine volume (cm3)
Baseline dominant fibroid
volume (cm3)

Mean

Std. Dev.

Min.

Max.

24.4
847.1
209.2

6.6
477.7
246.6

10
160
0.5

40
2264
1042

The symptom severity score, based on a 5‑point Likert scale, had a possible minimum
and maximum of 8 and 40, respectively

Table 3: The average percentage reduction of the symptom
severity scores, volume of the dominant fibroid, and volume
of the uterus, 3-6 months after UFE
Symptom severity score
% reduction
Uterine volume % reduction
Dominant fibroid % reduction

Mean

Std. Dev.

Min.

Max.

37.8

21.3

0

80

40.1
43.7

18.3
25.8

5
3

95
99

UFE: Uterine fibroid embolization

Table 4: The enhancement pattern of the dominant fibroids
before and after UFE
Enhancement pattern

Strong
Mild/moderate
None

Before UFE number (%)

After UFE number (%)

32 (54)
27 (46)
0 (0)

0 (0)
8 (14)
51 (86)

The absolute number and percentage of fibroids in each pattern of enhancement were
analyzed. All the dominant fibroids enhanced before UFE and none enhanced after UFE.
UFE: Uterine fibroid embolization

Table 5: Correlation between dominant fibroid volume, uterine
volume, and symptom severity score after UFE
Percentage volume reduction of the
dominant fibroid and uterus
Correlation between uterine volume
reduction and symptom score reduction
Correlation between dominant fibroid volume
reduction and symptom score reduction

Correlation
coefficient

P value

0.59

<0.001

−0.08

0.568

−0.14

0.278

The percentage volume reduction of the dominant fibroid and uterus was statistically
significant (P<0.001) as shown in the first row. However, no statistically significant
correlation was found between the percentage volume change of the dominant fibroid
and uterus and the symptom severity score, as shown in the second and third rows.
UFE: Uterine fibroid embolization
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Selected images of some of the patients are provided
[Figures 1–6].

and symptom score, and their correlation among this
African population.

DISCUSSION
UFE is a fairly new treatment option for women with
uterine fibroids in Kenya and sub‑Saharan Africa at
large. Data on both clinical and radiological response
is, therefore, lacking. This study was aimed at assessing
the response among pioneer African women in a tertiary
institution in Kenya.

Patient selection, UFE, and interpretation of findings
were carried out by an experienced team comprising an
interventional radiologist, consultant gynecologist, and
consultant radiologist. Imaging of the participants was
carried out in the same facility, using the same scanner and
standardized imaging protocol. The reviewers were blind
to clinical information and images were anonymized. All
these factors helped in reduction of bias during the study.

The catchment population of the institution is mainly
African, who are known to have high prevalence of uterine
fibroids, and larger and numerous fibroids compared to
other races.[7‑13] The study was, therefore, structured to
assess and detect the percentage change in the UV, DFV,

The high mean UV at baseline corresponding to 847 cm3,
more than 10 fibroids in 59% of participants, percentage
change of the dominant fibroid and the uterus being equal
to 43.7% and 40.1%, respectively, and lack of correlation
between the clinical and radiological outcome after UFE

180%(52)),%52,'63(53$7,(17
WR

WR

/2&$7,212)'20,1$17),%52,'

DERYH







,070
66



60



Pie Chart 1: The number of fibroids per respondent. The number of fibroids
per respondent was categorized into three groups: 1–5, 6–10, and >10. The
number of participants in each category was then presented as a percentage:
59% of the participants had more than 10 fibroids, 21% had between 6 and 10
fibroids, while 20% had less than 5 fibroids.

Pie Chart 2: The positions of the dominant fibroids. The intramural (IM) and
transmural (TM) dominant fibroids were lumped together due to difficulty
of the reviewers in correctly categorizing the two. Also, 78% of the fibroids
were intramural/transmural, 12% were submucosal (SM), while 10% were
subserosal (SS).

Figure 1: 28-year-old female presenting with menorrhagia and pelvic mass.
Post-contrast T1-weighted sagittal MRI image before UFE reveals two
enhancing fibroids (solid arrows).

Figure 2: 28-year-old female presenting with menorrhagia and pelvic mass.
Follow-up MRI post UFE, the fibroids demonstrate loss of enhancement
(arrows), but no significant change in volume.
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Figure 3: 33-year-old female presenting with mild pelvic pain and a palpable
pelvic mass. T1-weighted axial MRI image before UFE shows a single intramural
fibroid with heterogeneous (mild/moderate) enhancement pattern.

Figure 5: 36-year-old female presenting with pelvic mass, lower abdominal
pain, infertility, and menorrhagia. Follow-up MRI post UFE shows the fibroids
has completely regressed (arrow).

were the principal findings in this study. It is therefore clear
that UFE is a viable option for treating uterine fibroids in
an African population.
Assessment of the extent of uterine fibroid disease at
baseline allowed comparison of baseline and follow‑up
data and evaluation of possible interactions with the clinical
outcome. MRI showed significant volume reduction of
both uterus and dominant fibroid at short‑term follow‑up,
which corresponded to 43.7% and 40.1%, respectively. The
amount of UV and DFV reduction in this study is in the
range reported in other studies and case series, mainly
from the west. In the study by Reena et al., the mean
decrease in UV was from 588.6 cm3 to 393.1 cm3, which
resulted in a 33.5% change (P < 001). The reduction in the
dominant fibroid volume in our study was comparable to
these studies with a mean volume of 69.4 cm3 before UFE
and 41.4 cm3 after UAE, which resulted in a 40.1% volume
7

Figure 4: 36-year-old female presenting with pelvic mass, lower abdominal
pain, infertility, and menorrhagia. T1-weighted sagittal MRI image before UFE
reveals a large enhancing fibroid (thick arrow) and a small non-enhancing
fibroid (thin arrow).

Figure 6: 34 year old female presenting with heavy menses. T1-weighted
sagittal post-contrast MRI image before UFE shows bulky uterus with multiple
fibroids (arrows).

reduction (P < 001).[22] Similar observations were also made
by Andersen et al.,[25] Spies and colleagues,[26] and Walker
and Pelage,[27] who reported ranges between 35% and 55%.
Severe symptoms and presence of large and numerous
fibroids among the participants of this study are consistent
with what have been observed in other studies on African
and African‑American populations notably by Kjerulff
et al.[8] Spies and colleagues[26] originally validated their
symptom score questionnaire in a patient population with
uterine fibroids in comparison with a healthy control group.
The baseline symptom severity scores and short‑term
follow‑up in their patient population correspond to those
observed in this study. Similar observations have also been
made in a study by Scheurig et al.
No clear association between baseline UV and DFV, and
percentage UV and DFV reduction after UFE emerged from
Journal of Clinical Imaging Science | Vol. 5 | Issue 1 | Jan-Mar 2015
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the results of previously reported large case series.[26,28]
Likewise, in this study, no association was found between
the number of fibroids, the localization of the dominant
leiomyoma at baseline MRI, and the UV/DFV reduction
after UFE. In addition, no significant correlation between
improvement in symptoms and imaging findings was
identified. However, strong enhancement at baseline
correlated to a better outcome.
In the study by Reena et al., it was observed that clinical
and imaging response to UFE was lower in older patients
and those with larger fibroids/UV at presentation. Our
study was not powered to detect these differences. Future
studies may, therefore, look into these parameters. A study
in South Africa aimed at assessing the effect of large uterus
on the outcome of UFE did not, however, reveal significant
differences between those with UVs below and above
780 cm3. This is likely related to embolic particle distribution
per unit volume of the fibroid. This may also explain why
the response to UFE in our study is similar to that in the
west, even though our participants had, on average, large
and numerous fibroids. Other factors such as diet and
living conditions, which were not assessed in this study,
could also play a role. Future studies may, therefore, take
into consideration the number of embolic particles per
fibroid volume, environmental factors, and lifestyle of the
participants.
Significant reduction in the uterine and dominant fibroid
after UFE is due to sluggish or no blood flow in the uterine
arteries, which are the vessels that typically supply large
feeding branches to the fibroids. The enhancement of
fibroids is related to blood flow. Fibroids with good blood
flow, therefore, enhance strongly and vice versa. This
explains why fibroids which were strongly enhancing
at baseline had better response after UFE. Moderately
or mildly enhancing fibroids had lesser response due to
the fact that part of the fibroids had already undergone
degeneration at the time of embolization. Patient selection
is, therefore, important for successful UFE.
Lack of statistically significant correlation between
volume change of the uterus and dominant fibroid and
the symptom scores in our study has implications on the
clinicians and policy makers. The follow‑up MRI scans done
in many centers might not be warranted unless for specific
reasons like assessment of patients with complications. This
will likely reduce the cost of undergoing UFE and make it
more accessible in the developing world.

performed at the intended 3 months post UFE. Some
participants (approximately 10%) were scanned up to
6 months post UFE. The second limitation is that this was
a post graduate dissertation study, and therefore, funds
were limited. A small sample size was, therefore, chosen
and studied to only detect changes in the uterine and
dominant fibroid volumes and symptoms scores. Many
other parameters such as dietary and environmental factors
influencing response to treatment were not assessed.
Long‑term changes (more than 1 year) were also not
studied.

CONCLUSION
The response of uterine fibroids to embolization in the
African population is not different from the findings
reported in other studies from the west. The presence of
multiple and large fibroids in this study is consistent with
the case mix described in the studies of African‑American
populations.
Patient counseling should emphasize the independence
of volume reduction and symptom improvement. Volume
changes are of relevance for the radiologist in aiding
understanding of the evolution of the condition and
identifying potential technical treatment failures, but should
not be the main basis of evaluation of treatment success.
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